唐氏综合症小鼠模型中改变的大脑胆固醇机制:阿尔茨海默病的可能共同特征
Erica Staurenghi1, Gabriella Testa1, Valerio Leoni2
1Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy.
Antioxidants (Basel, Switzerland)
|April 27, 2024
概括
唐氏综合征 (DS) 和阿尔茨海默氏症 (AD) 分享大脑胆固醇失衡. 这项对Ts2小鼠的研究揭示了胆固醇代谢的改变,氧化应激增加和炎症,这表明神经退行症的常见途径.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 生物化学 生物化学
背景情况:
- 由于遗传因素,唐氏综合征 (DS) 与阿尔茨海默氏症 (AD) 有关,胆固醇稳定对大脑健康至关重要.
- 大脑胆固醇代谢的失调与AD神经炎症和氧化损伤有关,这表明在DS中可能会发生类似的过程.
研究的目的:
- 在DS的Ts2Cje (Ts2) 鼠标模型中调查胆固醇代谢,氧化醇水平,氧化应激和炎症.
- 为了比较Ts2小鼠中的这些因素与euploid对照,以确定与AD共享的病理机制.
主要方法:
- 对胆固醇代谢中的关键酶的基因表达的分析 (例如,HMG-CoA减少酶,24-脱胆固醇减少酶).
- 在小鼠大脑中量化胆固醇,氧醇和胆固醇自氧化产物.
- 评估炎症标志物,包括干扰素-α和干白素-6基因表达.
主要成果:
- Ts2小鼠对胆固醇合成酶的基因进行了下调,并降低了总胆固醇水平.
- 胆固醇氧化基因的改变表达和胆固醇自氧化产物的增加表明大脑氧化应激增加.
- 在Ts2小鼠中观察到炎症性细胞因子 (INTERFERON-ALFA,INTERLEUKIN-6) 的升级表达.
结论:
- DS和AD大脑在胆固醇代谢中表现出共同的乱和改变的氧胆固醇配置文件.
- 这些与胆固醇相关的变化可能会导致DS和AD神经退行症中观察到的氧化应激和炎症.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在CYP46A1中.联合国人权高专办24唐氏综合征是什么意思 唐氏综合征在HMGCR中,HMGCR是最重要的.胆固醇 胆固醇 胆固醇 是一种神经炎症是一种神经炎症.氧化应激是一种氧化应激.氧醇是一种氧醇.更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
